Geneva, July 14 -- International Clinical Trials Registry received information related to the study (NCT07042295) titled 'Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System' on June 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Locally Recurrent Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
Intervention:
Drug: Amivantamab and Recombinant Human Hyaluronidase
Procedure: Biospecimen Collection
Biological: Cetuximab
Procedure: Computed Tomography
Recruitment Statu...